icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Barcelona, Spain
13-17 April 2016
Back grey_arrow_rt.gif
No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/ Sofosbuvir
(LDV/SOF): Real-World Data from 2034 Genotype 1 Patients in the TRIO Network

  Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
NezamAfdhal1, Bruce Bacon2, Michael Curry1, Douglas Dieterich3, Steven L. Flamm4, Lauren Guest5, Kris V. Kowdley6,Yoori Lee5, NaokyTsai7, ZobairYounossi8
1Beth Israel Deaconess Medical Center, 2Saint Louis University School of Medicine,3Mount Sinai School of Medicine, 4Northwestern University Feinberg School of Medicine,5Trio Health Analytics,
6 Swedish Liver Center and Transplant Program, Swedish Medical Center, 7 Queens Medical Center, University of Hawaii, 8Center for Liver Diseases, Department of Medicine, InovaFairfax Hospital
PPI Study at AASLD 2015:
(HCV-TARGET) - Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study.....http://www.natap.org/2015/AASLD/AASLD_101.htm